Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00865501

Enrollment

Registered

2009-03-19

Start date

2008-03-31

Completion date

2009-12-31

Last updated

2012-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hypertension

Keywords

primary hypertension, aldosterone, left ventricular hypertrophy

Brief summary

The Renin-Angiotensin-Aldosterone-system is important in the development of cardiovascular organ damage caused by arterial hypertension. This study aims at evaluating the importance of aldosterone with regard to hypertension induced damage to the heart. In order to do this the investigators will perform a comparative cross-sectional study in hypertensives and normotensives. In addition as interventional part the hypertensives will be treated with a mineralocorticoid-receptor blocker (spironolactone).

Interventions

DRUGspironolactone

25mg per oral once daily

DRUGplacebo

placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis hypertension (BP higher than 139/89)

Exclusion criteria

* Antihypertensive pretreatment * Contraindications against spironolactone * Being unable to understand or comply with study procedures

Design outcomes

Primary

Measure	Time frame
left ventricular mass	8 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026